



Edition –19th

Date – July 2026

Portfolio – Growth

Halozyme Therapeutics - [HALO]

HALO Halozyme Therapeutics Inc. Nasdaq GS + BATS 7-Jul-2026 3:23pm Open 81.50 High 82.26 Low 80.61 Last 81.03 Volume 1.1M Chg +0.25 (+0.31%)



HALO Stock Breakdown

Dividend Yield*	N/A
Sector	Health Care
Industry	Biotechnology
EWM Initial Buy	6/4/2026
Closing Price on 6/4/2026	\$71.75
EWM Price Target	\$84

*As of 7/7/2026

HALO Synopsis

Economic Influence

Halozyme's revenue comes from royalties and licensing fees tied to its partners' drug sales, not consumer spending, which helps shield the company from the inflation and interest rate pressures.

Fundamental Factors

Halozyme has grown revenue every year for over a decade, with sales up nearly 40% this past year alone, while operating margins have climbed to 58%—a sign of a highly profitable, durable business

Technical Support

The daily chart of HALO shows a consolidation pattern that we believe will lead to a breakout to all time highs.

Industry Indicators

Major pharmaceutical companies are increasingly converting IV drug infusions into faster, at-home injections, and Halozyme has positioned itself as the go-to partner for this shift, most recently

Did you know?

- ENHANZE-enabled therapies have been commercialized in more than 100 countries, with over one million patients treated using the platform.
- In recent years, Halozyme has invested in advanced auto-injector technologies and acquired additional drug-delivery platforms to broaden its capabilities.
- Halozyme reported record 2025 revenue of approximately \$1.4 billion

Company Profile

- The company was founded in 1998.
- Based in San Diego, California.

See page 2 to read the FULL STORY



Edition –19th

Date – July 2026

Portfolio – Growth

Halozyme – Full Story

You may not know the name, but Halozyme is essentially the technology behind a range of revolutionary drug treatments. Its proprietary enzyme allows injectable cancer, autoimmune, and immunodeficiency drugs to be given as a quick at-home shot instead of an hours-long IV infusion at an infusion center.

The company has grown revenue every year for over a decade, with sales up 39% over the past year and operating margins climbing to 58%—a highly profitable and durable licensing model built around its patented rHuPH20 drug-delivery enzyme. Despite this growth and profitability, the stock trades at just 7.8x forward earnings, a steep discount to its peer average of 26.6x and well below its own 5-year average of 12.2x, suggesting the market hasn't fully priced in the durability of its earnings stream.

Turning to the technical picture, we believe investors are starting to buy into this story. The stock first showed up in our scanning process in early June, flagged by a favorable moving average setup and strong price action (green box). We entered the position shortly after, and the stock rallied from \$72 to \$82 without skipping a beat. Shares are now testing all-time highs, with resistance sitting at the dotted black line.

From here, we could see a Cup & Handle pattern take shape, with a pullback toward \$77 forming the "handle" before a potential move higher. This is a setup we like to see, as it could push our price target from \$84 up to \$95/share—a meaningful gain for the portfolio. We'll be watching closely for that pattern to confirm, with an eye toward adding to the position if it plays out.



Important Disclosures: Information presented is believed to be factual and up to date as of 7/7/2026. Different types of investments involve varying degrees of risk. Past performance is not a reliable indicator of current and future results. The information presented herein is intended for educational purposes only. The specifics of the activity presented by the EWM Asset Management team is intended for general information only. The actual impact to your personal portfolio is not represented by the statements made in this document and you should proactively review your monthly/quarterly statements or contact the office to speak to an Advisor to validate your specific transactions. EWM and its employees are not affiliated with any company mentioned in this document. Any charts, graphs, or visual aids presented herein are intended to demonstrate concepts which cannot be fully explained without the assistance of a professional from EWM. Readers should not in any way interpret these visual aids as a device with which to ascertain investment decisions or an investment approach. Only your professional adviser should interpret this information. Information above is provided by reports available in the Schwab Advisor Services™ research center and StockCharts.com. The dividend yield is calculated without the deduction of fees and expenses. The Standard and Poor's 500 is a stock market index tracking the stock performance of 500 large companies listed on stock exchanges in the United States.